The actemra (tocilizumab) market size has grown rapidly in recent years. It will grow from $5.71 million in 2025 to $6.32 million in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to established role of il 6 in inflammation, rising rheumatoid arthritis prevalence, strong clinical trial outcomes, biologic adoption in tertiary hospitals, regulatory approvals across indications.
The actemra (tocilizumab) market size is expected to see rapid growth in the next few years. It will grow to $9.34 million in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to increasing autoimmune disease burden, expansion into new inflammatory indications, growth of biologic infusion centers, improved early diagnosis rates, rising biologic therapy access. Major trends in the forecast period include expanded use in autoimmune and inflammatory disorders, growing adoption in cytokine release syndrome management, increased hospital based biologic administration, rising focus on early il 6 targeted intervention, enhanced long term safety monitoring of biologics.
The increasing prevalence of rheumatoid arthritis is expected to drive the growth of the Actemra (tocilizumab) market in the coming years. Rheumatoid arthritis is a chronic autoimmune disorder characterized by persistent joint inflammation, progressive joint damage, and a reduced quality of life, affecting millions of people worldwide. The condition is influenced by several factors, including smoking, obesity, environmental exposures, and hormonal influences. Actemra (tocilizumab) is widely used in the treatment of rheumatoid arthritis to reduce inflammation and prevent joint damage by blocking the interleukin-6 (IL-6) receptor, particularly in patients who do not respond adequately to other therapies. For example, in April 2024, according to data published by the National Institute for Health and Care Research (NIHR), a UK-based government agency, around 700,000 people in the United Kingdom were living with rheumatoid arthritis. In addition, in June 2024, the Australian Institute of Health and Welfare reported that approximately 514,000 people, or 2% of the population, were living with rheumatoid arthritis in Australia in 2022. In 2023, the disease accounted for 2% of the total disease burden and 16% of the burden related to musculoskeletal conditions. Rheumatoid arthritis was also associated with 1,322 deaths in 2022, corresponding to 5.1 deaths per 100,000 people and representing 0.7% of all deaths. As a result, the rising burden of rheumatoid arthritis is contributing to the growth of the Actemra (tocilizumab) market.
Major companies operating in the Actemra (tocilizumab) market are increasingly focusing on the development of advanced solutions, such as tocilizumab biosimilars, to strengthen their competitive position. Tocilizumab biosimilars are approved for the treatment of autoimmune diseases as well as COVID-19, offering cost-effective alternatives to the originator drug Actemra. For instance, in November 2023, Fresenius Kabi, a Germany-based healthcare company, launched Tyenne, the first tocilizumab biosimilar referencing RoActemra (tocilizumab) in the European Union. Tyenne is approved for the treatment of several inflammatory and immune-mediated conditions, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, cytokine release syndrome, and COVID-19.
In September 2024, Bio-Thera Solutions Ltd., a China-based biopharmaceutical company, partnered with Biogen Inc. to publish Phase 3 clinical trial data for TOFIDENCE (BAT1806/BIIB800), an approved biosimilar to Actemra/RoActemra (tocilizumab). Marketed as TOFIDENCE, this biosimilar is intended to improve treatment accessibility for patients with autoimmune disorders. Biogen Inc. is a US-based biotechnology company specializing in therapies for neurological and autoimmune diseases.
Major companies operating in the actemra (tocilizumab) market are Roche Holding AG, Fresenius Kabi.
North America was the largest region in the actemra (Tocilizumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the actemra (tocilizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the actemra (tocilizumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have had a measurable impact on the actemra market by raising costs for imported biologic raw materials and injectable drug components. These effects are most prominent in hospital pharmacy supply chains across north america and europe. Higher tariffs have created pricing and reimbursement pressures for infusion based biologics. At the same time, tariffs are supporting domestic biologic manufacturing capacity expansion. This strengthens long term supply chain resilience and regional self sufficiency.
The actemra (tocilizumab) market research report is one of a series of new reports that provides actemra (tocilizumab) market statistics, including actemra (tocilizumab) industry global market size, regional shares, competitors with a actemra (tocilizumab) market share, detailed actemra (tocilizumab) market segments, market trends and opportunities, and any further data you may need to thrive in the actemra (tocilizumab) industry. This actemra (tocilizumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Actemra (tocilizumab) is a prescription biologic drug classified as an interleukin-6 (IL-6) receptor antagonist and is used to treat a range of autoimmune and inflammatory disorders. It works by blocking IL-6, a cytokine that plays a key role in inflammation, thereby helping to reduce symptoms and slow disease progression in conditions such as rheumatoid arthritis, giant cell arteritis, and cytokine release syndrome.
The main product types of Actemra (tocilizumab) are minimum purity below 98%, minimum purity between 98% and 99%, and minimum purity above 99%. Products with a minimum purity below 98% include tocilizumab formulations that contain higher levels of impurities or residual components, which may influence overall safety and effectiveness. The available dosage forms include injection, solution, and concentrate, with routes of administration such as oral, parenteral, and others. The drug is distributed through hospital pharmacies, retail pharmacies, and online pharmacies and is used in applications including cytokine release syndrome (CRS), systemic juvenile idiopathic arthritis (SJIA), giant cell arteritis (GCA), and rheumatoid arthritis (RA).
The actemra (tocilizumab) market consists of sales of intravenous (IV) and subcutaneous (SC) formulations used to treat autoimmune and inflammatory diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The actemra (tocilizumab) market size is expected to see rapid growth in the next few years. It will grow to $9.34 million in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to increasing autoimmune disease burden, expansion into new inflammatory indications, growth of biologic infusion centers, improved early diagnosis rates, rising biologic therapy access. Major trends in the forecast period include expanded use in autoimmune and inflammatory disorders, growing adoption in cytokine release syndrome management, increased hospital based biologic administration, rising focus on early il 6 targeted intervention, enhanced long term safety monitoring of biologics.
The increasing prevalence of rheumatoid arthritis is expected to drive the growth of the Actemra (tocilizumab) market in the coming years. Rheumatoid arthritis is a chronic autoimmune disorder characterized by persistent joint inflammation, progressive joint damage, and a reduced quality of life, affecting millions of people worldwide. The condition is influenced by several factors, including smoking, obesity, environmental exposures, and hormonal influences. Actemra (tocilizumab) is widely used in the treatment of rheumatoid arthritis to reduce inflammation and prevent joint damage by blocking the interleukin-6 (IL-6) receptor, particularly in patients who do not respond adequately to other therapies. For example, in April 2024, according to data published by the National Institute for Health and Care Research (NIHR), a UK-based government agency, around 700,000 people in the United Kingdom were living with rheumatoid arthritis. In addition, in June 2024, the Australian Institute of Health and Welfare reported that approximately 514,000 people, or 2% of the population, were living with rheumatoid arthritis in Australia in 2022. In 2023, the disease accounted for 2% of the total disease burden and 16% of the burden related to musculoskeletal conditions. Rheumatoid arthritis was also associated with 1,322 deaths in 2022, corresponding to 5.1 deaths per 100,000 people and representing 0.7% of all deaths. As a result, the rising burden of rheumatoid arthritis is contributing to the growth of the Actemra (tocilizumab) market.
Major companies operating in the Actemra (tocilizumab) market are increasingly focusing on the development of advanced solutions, such as tocilizumab biosimilars, to strengthen their competitive position. Tocilizumab biosimilars are approved for the treatment of autoimmune diseases as well as COVID-19, offering cost-effective alternatives to the originator drug Actemra. For instance, in November 2023, Fresenius Kabi, a Germany-based healthcare company, launched Tyenne, the first tocilizumab biosimilar referencing RoActemra (tocilizumab) in the European Union. Tyenne is approved for the treatment of several inflammatory and immune-mediated conditions, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, cytokine release syndrome, and COVID-19.
In September 2024, Bio-Thera Solutions Ltd., a China-based biopharmaceutical company, partnered with Biogen Inc. to publish Phase 3 clinical trial data for TOFIDENCE (BAT1806/BIIB800), an approved biosimilar to Actemra/RoActemra (tocilizumab). Marketed as TOFIDENCE, this biosimilar is intended to improve treatment accessibility for patients with autoimmune disorders. Biogen Inc. is a US-based biotechnology company specializing in therapies for neurological and autoimmune diseases.
Major companies operating in the actemra (tocilizumab) market are Roche Holding AG, Fresenius Kabi.
North America was the largest region in the actemra (Tocilizumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the actemra (tocilizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the actemra (tocilizumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have had a measurable impact on the actemra market by raising costs for imported biologic raw materials and injectable drug components. These effects are most prominent in hospital pharmacy supply chains across north america and europe. Higher tariffs have created pricing and reimbursement pressures for infusion based biologics. At the same time, tariffs are supporting domestic biologic manufacturing capacity expansion. This strengthens long term supply chain resilience and regional self sufficiency.
The actemra (tocilizumab) market research report is one of a series of new reports that provides actemra (tocilizumab) market statistics, including actemra (tocilizumab) industry global market size, regional shares, competitors with a actemra (tocilizumab) market share, detailed actemra (tocilizumab) market segments, market trends and opportunities, and any further data you may need to thrive in the actemra (tocilizumab) industry. This actemra (tocilizumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Actemra (tocilizumab) is a prescription biologic drug classified as an interleukin-6 (IL-6) receptor antagonist and is used to treat a range of autoimmune and inflammatory disorders. It works by blocking IL-6, a cytokine that plays a key role in inflammation, thereby helping to reduce symptoms and slow disease progression in conditions such as rheumatoid arthritis, giant cell arteritis, and cytokine release syndrome.
The main product types of Actemra (tocilizumab) are minimum purity below 98%, minimum purity between 98% and 99%, and minimum purity above 99%. Products with a minimum purity below 98% include tocilizumab formulations that contain higher levels of impurities or residual components, which may influence overall safety and effectiveness. The available dosage forms include injection, solution, and concentrate, with routes of administration such as oral, parenteral, and others. The drug is distributed through hospital pharmacies, retail pharmacies, and online pharmacies and is used in applications including cytokine release syndrome (CRS), systemic juvenile idiopathic arthritis (SJIA), giant cell arteritis (GCA), and rheumatoid arthritis (RA).
The actemra (tocilizumab) market consists of sales of intravenous (IV) and subcutaneous (SC) formulations used to treat autoimmune and inflammatory diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Actemra (Tocilizumab) Market Characteristics
3. Actemra (Tocilizumab) Market Supply Chain Analysis
4. Global Actemra (Tocilizumab) Market Trends and Strategies
5. Actemra (Tocilizumab) Market Analysis of End Use Industries
7. Global Actemra (Tocilizumab) Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Actemra (Tocilizumab) Total Addressable Market (TAM) Analysis for the Market
9. Actemra (Tocilizumab) Market Segmentation
10. Actemra (Tocilizumab) Market Regional and Country Analysis
11. Asia-Pacific Actemra (Tocilizumab) Market
12. China Actemra (Tocilizumab) Market
13. India Actemra (Tocilizumab) Market
14. Japan Actemra (Tocilizumab) Market
15. Australia Actemra (Tocilizumab) Market
16. South Korea Actemra (Tocilizumab) Market
17. Western Europe Actemra (Tocilizumab) Market
18. UK Actemra (Tocilizumab) Market
19. Germany Actemra (Tocilizumab) Market
20. France Actemra (Tocilizumab) Market
21. Eastern Europe Actemra (Tocilizumab) Market
22. North America Actemra (Tocilizumab) Market
23. USA Actemra (Tocilizumab) Market
24. Canada Actemra (Tocilizumab) Market
25. South America Actemra (Tocilizumab) Market
26. Middle East Actemra (Tocilizumab) Market
27. Africa Actemra (Tocilizumab) Market
29. Actemra (Tocilizumab) Market Competitive Landscape and Company Profiles
32. Actemra (Tocilizumab) Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
Actemra (Tocilizumab) Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses actemra (tocilizumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for actemra (tocilizumab)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The actemra (tocilizumab) market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Min Purity Less Than 98%; Min Purity 98%-99%; Min Purity More Than 99%2) By Dosage: Injection; Solution; Concentrate
3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
5) By Application: Cytokine Release Syndrome (CRS); Systemic Juvenile Idiopathic Arthritis (sJIA); Giant Cell Arteritis (GCA); Rheumatoid Arthritis (RA)
Companies Mentioned: Roche Holding AG; Fresenius Kabi
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Actemra (Tocilizumab) market report include:- Roche Holding AG
- Fresenius Kabi
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 6.32 Million |
| Forecasted Market Value ( USD | $ 9.34 Million |
| Compound Annual Growth Rate | 10.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 3 |
